ZM-241,385

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
ZM-241,385
ZM241385.png
Names
IUPAC name
4-(2-(7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.216.533
Properties
C16H15N7O2
Molar mass 337.343 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

ZM-241,385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.[1]

In animal models, ZM-241,385 has been shown to protect against beta amyloid neurotoxicity and therefore may be useful as a treatment for Alzheimer's disease.[2] ZM-241,385 has also been shown to enhance L-DOPA derived dopamine release and therefore may be useful in the treatment of Parkinson's disease.[3]

References[edit]

  1. ^ Palmer TM, Poucher SM, Jacobson KA, Stiles GL (December 1995). "125I-4-(2-(7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5) triazin-5-yl-amino)ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor". Molecular Pharmacology. 48 (6): 970–4. PMC 3479638. PMID 8848012.
  2. ^ Dall'Igna OP, Porciúncula LO, Souza DO, Cunha RA, Lara DR, Dall'lgna OP (April 2003). "Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity". British Journal of Pharmacology. 138 (7): 1207–9. doi:10.1038/sj.bjp.0705185. PMC 1573785. PMID 12711619.
  3. ^ Gołembiowska K, Dziubina A (September 2004). "Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats". Neuropharmacology. 47 (3): 414–26. doi:10.1016/j.neuropharm.2004.04.018. PMID 15275831.

External links[edit]

ZM+241385 at the US National Library of Medicine Medical Subject Headings (MeSH)